The Globe and Mail reports in its Friday, Nov. 24, edition that Raymond James analyst Steve Hansen has lowered his recommendation for Deveron by two levels to "market perform" from "strong buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Hansen slashed his share target by 40 cents to 35 cents, matching the consensus. Mr. Hansen says in a note: "While Deveron's core soil lab fertility business continues to exceed expectations, a sharp slowdown in the firm's ancillary carbon business has collided with an elevated cost structure to introduce near-term margin headwinds heading into the company's busiest quarter. While we expect these pressures can be ultimately be rectified, we have elected to step to the sidelines until greater visibility emerges." The Globe reported on June 22, 2022, and June 2, 2023, that Mr. Hansen was sticking with his "strong buy" call on Deveron. In the first item Mr. Hansen called Deveron's new carbon platform "unique" with a "compelling" growth outlook. The shares were then worth 47 cents and 34.5 cents.